AXSM News and Press, Axsome Therapeutics Inc. From 01/02/23

Summary TG Therapeutics, Inc. is set to launch Briumvi with an experienced in-house team. There are several factors conducive to launch success. Nevertheless, uncertainty remains. If TG Therapeutics can secure a sales/marketing partnership, the company will likely make a successful ...

Summary Axsome has one pending approval and two pending NDAs coming up in 2023. They are adequately funded, if not very strongly. I will hold on to my post-profit shares for one more year. I have been covering Axsome Therapeutics ( AXSM ) since 2020, and have been cons...

The stock market has been performing better recently, with the S&P 500 up by nearly 5% in the past three months, although it remains down 18% over the past year. Will this mini-rally extend well into 2023? It's hard to say. Economic or market conditions could worsen and drag down the stoc...

Businesses that are surefire bets for continued growth can make for solid investment opportunities. While dividend stocks can provide safety and give you recurring income, strong growth stocks can generate more significant returns in the long run. If you've got $5,000 you can afford to invest rig...

Moderna (NASDAQ: MRNA) and Axsome Therapeutics (NASDAQ: AXSM) are early in their revenue stories. Moderna launched its first product -- the COVID-19 vaccine -- in 2020. Axsome started selling its first two products -- a sleep disorder drug and an antidepressant -- this year. Bot...

Summary On Monday, Madrigal Pharmaceuticals announced a best-case dataset from its phase 3 trial in NASH. This opens up a Huge market for the company. Madrigal Pharmaceuticals stock is up 4x: what you should do now. I have been bullish on Madrigal ( MDGL ) since 20...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the hottest biotech stocks are safe and recession-proof. After all, we can’t stop people from aging – at least, not yet. We can’t stop people from seeking treatments for a myriad of issues. Plus, th...

Axsome Therapeutics (NASDAQ: AXSM) has done something most other stocks haven't been able to do this year: It's beaten the bear market. The shares are heading for a 111% gain as the S&P 500 heads for a 16% loss. Axsome's performance isn't random -- there's a clear reason for it....

Citigroup CEO Jane Fraser expects a recession in 2023. So does JPMorgan Chase CEO Jamie Dimon. Even Treasury Secretary Janet Yellen recently acknowledged that there's a real risk of a U.S. recession next year. Such concerns could be overblown. Then again, maybe they're not. What should ...

Momentum: In physics, it's a measure of mass and velocity. For stocks, it's the velocity of price changes. But in both realms, momentum can be sustained or it can be lost. Investors obviously prefer stocks with momentum that can keep it going. With this in mind, we asked three Motley Fool con...